Mind Medicine Mindmed Inc (MNMD)

May 28, 2025, 7:00 AM EDT - 8 days ago

MindMed to Participate in June Investor Conferences

May 27, 2025, 7:00 AM EDT - 9 days ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 19, 2025, 4:01 PM EDT - 17 days ago

MindMed Announces New Employee Inducement Grants

May 13, 2025, 7:00 AM EDT - 23 days ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 8, 2025, 9:55 AM EDT - 4 weeks ago

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 4 weeks ago

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

Apr 24, 2025, 7:00 AM EDT - 6 weeks ago

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 15, 2025, 7:00 AM EDT - 7 weeks ago

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Mar 17, 2025, 7:00 AM EDT - 2 months ago

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 6, 2025, 12:10 PM EST - 3 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 7:00 AM EST - 3 months ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mar 4, 2025, 7:00 AM EST - 3 months ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

Feb 20, 2025, 7:00 AM EST - 3 months ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 4, 2025, 7:00 AM EST - 4 months ago

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 7:00 AM EST - 4 months ago

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Dec 19, 2024, 7:00 AM EST - 6 months ago

MindMed to Be Added to the Nasdaq Biotechnology Index

Dec 16, 2024, 7:00 AM EST - 6 months ago

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Dec 11, 2024, 7:00 AM EST - 6 months ago

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Dec 5, 2024, 7:00 AM EST - 6 months ago

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Dec 3, 2024, 7:00 AM EST - 6 months ago

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

Nov 18, 2024, 7:00 AM EST - 7 months ago

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Nov 13, 2024, 7:00 AM EST - 7 months ago

MindMed to Participate in Upcoming Investor Conferences

Nov 10, 2024, 9:55 AM EST - 7 months ago

Mind Medicine: No News = Good News

Nov 7, 2024, 8:06 PM EST - 7 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 7 months ago

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Nov 4, 2024, 4:04 PM EST - 7 months ago

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

Oct 24, 2024, 7:00 AM EDT - 8 months ago

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

Sep 4, 2024, 7:00 AM EDT - 9 months ago

MindMed to Participate in September Investor Conferences

Aug 15, 2024, 12:30 PM EDT - 10 months ago

Psychedelic Stocks: Focus On Their Cash

CMPS

Aug 13, 2024, 11:21 AM EDT - 10 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:44 AM EDT - 10 months ago

MindMed readying Phase III trials for LSD therapy to treat anxiety

Aug 13, 2024, 7:01 AM EDT - 10 months ago

Pacific Defense Announces US Army CMFF Program Team

MRNS

Aug 13, 2024, 7:00 AM EDT - 10 months ago

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

Aug 12, 2024, 12:47 PM EDT - 10 months ago

FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates

Aug 12, 2024, 12:12 PM EDT - 10 months ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

ATAI CMPS CYBN

Aug 9, 2024, 8:44 AM EDT - 10 months ago

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

Aug 9, 2024, 6:00 AM EDT - 10 months ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Aug 7, 2024, 2:29 PM EDT - 10 months ago

MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy

Aug 6, 2024, 4:01 PM EDT - 10 months ago

MindMed to Present at Canaccord Genuity's 44th Annual Growth Conference

Aug 6, 2024, 7:00 AM EDT - 10 months ago

MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update

Jul 29, 2024, 7:00 AM EDT - 11 months ago

MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

Jul 17, 2024, 7:00 AM EDT - 11 months ago

MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

Jun 28, 2024, 7:00 AM EDT - 1 year ago

MindMed to be Included in Russell 2000® and Russell 3000® Indexes

Jun 21, 2024, 7:00 AM EDT - 1 year ago

MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 20, 2024, 7:00 AM EDT - 1 year ago

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

Jun 5, 2024, 11:46 AM EDT - 1 year ago

MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors

May 28, 2024, 7:00 AM EDT - 1 year ago

MindMed to Participate in June Conferences

May 23, 2024, 12:15 PM EDT - 1 year ago

Psychedelics Closer To Commercialization; Compass Far And Away The Leader

CMPS

May 9, 2024, 4:01 PM EDT - 1 year ago

MindMed to Participate at May Investor Conferences

May 9, 2024, 8:00 AM EDT - 1 year ago

New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US